From Concept to Clinic: Integrated Strategic Support
Alacrita's Enterprise Development practice supports life-science ventures from first capital planning through later development milestones.
We combine market research, scientific insight, and operating experience to craft investor-ready business plans, refine fundraising narratives, provide interim C-suite leadership, shape platform-technology strategy, and, when needed, advise on later-stage planning. Because capital strategy, development execution, and downstream commercial considerations are connected, our integrated approach keeps decisions aligned and prevents the hand-offs that slow progress. Drawing on decades of real-world industry experience, we deliver evidence-based strategies that give investors the clarity they need to commit capital.
Where We Can Deliver Maximum Impact
Proven Expertise Meets Hands-On Execution
Whether you are sizing an addressable market for a Seed round, mapping the milestones needed for Series B, steering a virtual biotech through a leadership gap, or pressure testing how today's choices affect future market entry, we deliver the clarity and confidence your team needs to move forward. Our senior consultants have all held operating and leadership roles in the industry - we've been where you are. This firsthand experience, combined with our integrated approach, ensures guidance that is practical, timely, and actionable.
Our Services
Business Plans & Fundraising Support
A sound strategy is essential to healthcare investors at all stages of corporate development. We also prepare investor and partnering materials — pitch decks, websites, and messaging — that translate complex science into compelling opportunities for sophisticated evaluators.
Learn moreVirtual Biotech, Interim CXO
Helping you advance programs by providing seasoned operators ready to step in, when you're not in position to permanently hire.
Learn moreTechnology Platform Strategy
Strategic guidance for platform technology developers making critical decisions about partnerships, business models, indication prioritization and regulatory pathways.
Learn moreFor companies exploring independent commercialization, we also provide strategic launch planning to map the budget, resources, and timeline required — helping inform partnership vs. go-it-alone decisions during early clinical stages. Learn more about launch planning
Your roadmap to funded, executable progress
Investor ready business plans and fundraising materials that stand up to diligence
Interim CXO leadership with ongoing Alacrita strategic oversight to keep virtual programs focused and capital efficient
Platform roadmaps that link near term data packages to long term value creation and partnering options
Objective planning input for later development and market preparation when timing warrants it
Coordinated support across scientific, operational, and business work streams - all orchestrated by Alacrita's experienced core team
Why biotechs need advisors who've seen the full development arc
Raise capital on plans investors view as credible
Evidence-based strategies built by consultants who have raised capital, led development programs, and advised boards — not frameworks from generalists.
Move development forward with interim leadership
Experienced functional leaders with Alacrita oversight throughout — not independent contractors you manage yourself.
Make early choices that preserve future optionality
Guidance from consultants averaging 20 years in operating roles who understand how today's decisions affect pricing, access, and partnership leverage.
That continuity is increasingly what investors expect and what single-focus firms often leave as a gap.
Expertise Precisely Tailored to Your Needs
Alacrita's core team draws on a carefully curated network of more than 350 senior consultants assembled over the past fifteen years. These consultants average 20 years of experience across clinical, regulatory, CMC, commercial, and business development functions, spanning every major therapy area and product modality. Importantly, Alacrita maintains oversight of every engagement - we don't simply make introductions. Our core team, all with deep industry experience, orchestrates the right expertise at the right time, ensuring seamless integration and strategic continuity throughout your project.
For Investors
Alacrita also works directly with VCs, private equity, and institutional investors — providing due diligence, portfolio company support, valuation, and execution services. Learn about our investor services →
Case Studies
Business plan and fundraising for cell therapy company
Series A Fundraising: Development Strategy for Oncology Small Molecule Startup
Frequently Asked Questions
How does Alacrita's engagement model work?
+Alacrita's core team leads every engagement, manages deliverables, and provides continuity throughout — whether it's a 6-week business plan project or an 18-month interim CMO role. Our consultants work for Alacrita, not as independent contractors you manage yourself.
What stage companies does Alacrita work with?
+We work with life science companies at all stages, from pre-seed ventures developing their first business plans through established companies approaching launch. We're particularly well-suited for companies at critical inflection points: preparing for Series A, transitioning from preclinical to clinical, navigating an unexpected leadership gap, or building the strategic foundation for their next financing round.
What interim leadership roles does Alacrita provide?
+Interim and fractional executives across clinical, regulatory, CMC, and scientific functions. This includes interim CMOs, VP/Head of CMC, VP Regulatory Affairs, Chief Scientific Officers, VP Clinical Operations, VP Preclinical Development, and other functional leadership roles. Engagements vary based on need — some are full-time during executive transitions, others are fractional for ongoing strategic support.
Can Alacrita consultants attend board meetings and investor calls?
+Yes. Our interim executives regularly present to boards, participate in investor meetings, and represent companies in discussions with partners and regulatory agencies. For virtual and semi-virtual biotechs, this is often a core part of the engagement — providing the senior scientific and clinical presence that investors expect.
Contact Us
Reach out today for more information on our enterprise development services.